Catalogo Articoli (Spogli Riviste)

OPAC HELP

Titolo:
A PLACEBO-CONTROLLED EVALUATION OF ROPINIROLE, A NOVEL D-2 AGONIST, AS SOLE DOPAMINERGIC THERAPY IN PARKINSONS-DISEASE
Autore:
BROOKS DJ; ABBOTT RJ; LEES AJ; MARTIGNONI E; PHILCOX DV; RASCOL O; ROOS RAC; SAGAR HJ;
Indirizzi:
HAMMERSMITH HOSP,ROYAL POSTGRAD MED SCH,DEPT NEUROL,DU CANE RD LONDONW12 0NN ENGLAND LEICESTER ROYAL INFIRM,DEPT NEUROL LEICESTER LEICS ENGLAND MIDDLESEX HOSP,DEPT NEUROL LONDON W1N 8AA ENGLAND UNIV PAVIA,NEUROL INST C MONDINO I-27100 PAVIA ITALY GROOTE SCHUUR HOSP,DEPT NEUROL ZA-7925 CAPE TOWN SOUTH AFRICA INSERM U455,CLIN INVEST CTR,DEPT CLIN PHARMACOL TOULOUSE FRANCE LEIDEN UNIV,MED CTR LEIDEN NETHERLANDS ROYAL HALLAMSHIRE HOSP,DEPT NEUROL SHEFFIELD S10 2JF S YORKSHIRE ENGLAND
Titolo Testata:
Clinical neuropharmacology
fascicolo: 2, volume: 21, anno: 1998,
pagine: 101 - 107
SICI:
0362-5664(1998)21:2<101:APEORA>2.0.ZU;2-Y
Fonte:
ISI
Lingua:
ENG
Soggetto:
5-YEAR FOLLOW-UP; L-DOPA; MOTOR FLUCTUATIONS; LEVODOPA; BROMOCRIPTINE; NEURONS; CELLS; RATS;
Keywords:
PARKINSONS DISEASE; ROPINIROLE; DE NOVO;
Tipo documento:
Review
Natura:
Periodico
Settore Disciplinare:
Science Citation Index Expanded
Science Citation Index Expanded
Citazioni:
30
Recensione:
Indirizzi per estratti:
Citazione:
D.J. Brooks et al., "A PLACEBO-CONTROLLED EVALUATION OF ROPINIROLE, A NOVEL D-2 AGONIST, AS SOLE DOPAMINERGIC THERAPY IN PARKINSONS-DISEASE", Clinical neuropharmacology, 21(2), 1998, pp. 101-107

Abstract

The efficacy and safety of ropinirole, a novel nonergot dopamine D-2-like receptor agonist, was assessed as monotherapy for the treatment of patients with early-stage Parkinson's disease. In this double-blind,multicenter trial, patients were randomly allocated in a ratio of 2:1to receive, over a 12-week period, either ropinirole or placebo. Clinical status was assessed using the Unified Parkinson's Disease Rating Scale (UPDRS), Clinician's Global Evaluation (CGE), and a finger-tapping score. In all, 41 patients received ropinirole and 22 received placebo. The end-point analysis, on an intention-to-treat basis, revealed a significant difference (p = 0.018) in improvement in UPDRS motor score from baseline between treatment groups (ropinirole, 43.4%; and placebo, 21.0%). Other parameters, including the number of responders and improvement in CGE, showed similar results. Three patients in the ropinirole group and one patient in the placebo group discontinued the study because of adverse events. There was no significant difference between the treatment groups in the overall incidence of adverse events. Although the dopaminergic side effects were reported significantly morefrequently in the ropinirole group than in the placebo group (dizziness, p = 0.0326; nausea, p = 0.001; and somnolence, p = 0.005), none necessitated study withdrawal. There was no evidence of any chronic effect of the study medication on vital signs. In conclusion, ropinirole is a safe and well-tolerated drug and, as monotherapy, provided significant therapeutic benefit compared with placebo to patients in the early stages of Parkinson's disease.

ASDD Area Sistemi Dipartimentali e Documentali, Università di Bologna, Catalogo delle riviste ed altri periodici
Documento generato il 04/07/20 alle ore 17:13:36